Sculptor Capital LP lifted its stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 484.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,714,015 shares of the medical research company's stock after buying an additional 1,420,569 shares during the quarter. Bruker comprises about 1.3% of Sculptor Capital LP's portfolio, making the stock its 11th largest holding. Sculptor Capital LP owned approximately 1.13% of Bruker worth $100,476,000 as of its most recent filing with the SEC.
Other hedge funds also recently modified their holdings of the company. UMB Bank n.a. grew its holdings in shares of Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after purchasing an additional 248 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Bruker by 41.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock worth $78,000 after buying an additional 390 shares in the last quarter. Parvin Asset Management LLC purchased a new stake in Bruker in the fourth quarter valued at approximately $112,000. Finally, GeoWealth Management LLC raised its stake in shares of Bruker by 1,093.9% during the fourth quarter. GeoWealth Management LLC now owns 2,137 shares of the medical research company's stock worth $125,000 after acquiring an additional 1,958 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.
Bruker Stock Performance
Shares of BRKR stock traded up $0.39 during trading hours on Tuesday, reaching $38.19. 2,034,638 shares of the company's stock were exchanged, compared to its average volume of 1,607,816. The company has a market cap of $5.79 billion, a P/E ratio of 50.25, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. Bruker Co. has a 1 year low of $34.10 and a 1 year high of $78.94. The company's 50 day moving average is $40.05 and its two-hundred day moving average is $50.17.
Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.01. The firm had revenue of $801.40 million during the quarter, compared to the consensus estimate of $763.83 million. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The firm's revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.53 EPS. Equities research analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.
Bruker Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Monday, June 16th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Monday, June 16th. Bruker's dividend payout ratio is presently 38.46%.
Analysts Set New Price Targets
Several equities analysts have commented on BRKR shares. The Goldman Sachs Group lowered their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Citigroup dropped their price target on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Stifel Nicolaus dropped their price objective on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. Finally, Wells Fargo & Company dropped their price objective on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $60.10.
Check Out Our Latest Analysis on BRKR
Bruker Company Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
